Focal Therapy Remains Underutilized in Nonmetastatic Prostate Cancer, Often Deemed Inappropriate
Source Summary
A research letter published in JAMA on August 13 found that focal therapy use remains uncommon across all risk groups in patients with nonmetastatic prostate cancer. The study determined that focal therapy was classified as inappropriate in approximately half of the cases where it was used.
Why it matters
The findings highlight a significant gap between the limited adoption of focal therapy and its frequent misapplication in nonmetastatic prostate cancer treatment, suggesting potential inefficiencies in clinical practice.
